Key Stats for HIMS Stock
- Price Change for $HIMS stock: 16%
- Current Share Price: $63
- 52-Week High: $73
- $HIMS Stock Price Target: $47
What Happened?
HIMS (HIMS) stock jumped 16% on Thursday after the telehealth company announced its expansion into perimenopause and menopause treatment, marking a significant step into women’s hormonal health.
HIMS launched personalized treatment plans for women experiencing perimenopause and menopause symptoms.
Eligible customers can now work with licensed providers on the platform to access prescription medications, including estradiol and progesterone, in multiple forms like pills, patches, and creams.
The treatments target common symptoms such as hot flashes, night sweats, mood changes, sleep problems, and skin and hair changes.
The move addresses a clear gap in women’s healthcare. Around 1.3 million women in the US experience menopause each year, but only about 30% of OB/GYN residency programs provide formal menopause training.
This leaves many women navigating symptoms on their own. Hers, which already serves over half a million subscribers, is using its scale to change that dynamic.
Dr. Jessica Shepherd, Chief Medical Officer of Hers, emphasized that this isn’t just about medication, but also about building a platform women can trust for the care they need.
The company expects to introduce an expanded range of treatment options next year. Hers is on track to surpass $1 billion in annual revenue in 2026, and this new specialty could accelerate that trajectory.
See analysts’ growth forecasts and price targets for HIMS stock (It’s free!) >>>
What the Market Is Telling Us About HIMS Stock
The 16% gain in HIMS stock suggests investors view this expansion as a meaningful growth catalyst. The perimenopause and menopause market represents a massive opportunity with an estimated 50 million women affected in the US alone.
Hormone replacement therapy addresses conditions that have been under-recognized and under-treated in traditional healthcare settings for decades.
Just days earlier, HIMS stock dropped 6.5% after Bank of America highlighted weakening order trends and lowered its fourth-quarter revenue forecast to $590 million, 6.5% below consensus.
The report noted orders were down 16% year-over-year in September and cited concerns about slowing core growth and increased competition.
The expansion of hormonal health offerings gives Hims & Hers a fresh growth driver beyond its core offerings in sexual health, dermatology, and weight loss.
The company’s second quarter results showed strong momentum with revenue growing 73% year-over-year to $545 million while maintaining adjusted EBITDA margins above 15%.
With a subscriber base of 2.4 million, investors should note that HIMS stock remains highly volatile, with 98 moves greater than 5% over the past year.
While the recent product launch is positive, HIMS faces near-term headwinds from its GLP-1 weight loss business transition and competitive pressures that were flagged in the recent Bank of America report.
The success of this hormonal health offering will be crucial to monitor as a potential counterbalance to those challenges.
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!